Since joining Myriad in December 2023, Sam has played an integral role in shaping the Company’s long-term growth strategy, while delivering new perspectives and expertise to advance our business ...
Myriad Genetics Chief Executive Paul J. Diaz will leave the company April 30 to return to private equity firm Cressey & Co., where he will be a managing partner. The former Kindred Healthcare CEO was ...
Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The ...
Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management ...